Javier Vazquez-Bourgon

Dr. Javier Vazquez-Bourgon

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RBRachel M. Brouwer
Rachel M. Brouwer
MKMarieke Klein
Marieke Klein
KGKatrina Grasby
Katrina Grasby
HSHugo G. Schnack
Hugo G. Schnack
NJNeda Jahanshad
Neda Jahanshad
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol

9 December 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
CCConstantinos Constantinides
Constantinos Constantinides
LHLaura K. M. Han
Laura K. M. Han
CAClara Alloza
Clara Alloza
LALinda Antonella Antonucci
Linda Antonella Antonucci
CACelso Arango
Celso Arango
EWEsther Walton
Esther Walton
Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18–72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18–73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen’s d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.

28 March 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DSDick Schijven
Dick Schijven
MPMerel C. Postema
Merel C. Postema
MFMasaki Fukunaga
Masaki Fukunaga
JMJunya Matsumoto
Junya Matsumoto
KMKenichiro Miura
Kenichiro Miura
CFClyde Francks
Clyde Francks
Left–right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case–control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case–control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case–control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case–control status. Subtle case–control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia.

20 November 2020 in Schizophrenia
Verified
Journal Article
Open access
PDF file
RARosa Ayesa-Arriola
Rosa Ayesa-Arriola
VFVíctor Ortíz-García de la Foz
Víctor Ortíz-García de la Foz
ESEsther Setién-Suero
Esther Setién-Suero
MRMaría Luz Ramírez-Bonilla
María Luz Ramírez-Bonilla
PSPaula Suárez-Pinilla
Paula Suárez-Pinilla
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
While sex differences in schizophrenia have long been reported and discussed, long-term sex differences in outcomes among first episode of psychosis (FEP) patients in terms of the efficacy of Early Intervention Services (EIS) has been an under-explored area. A total of 209 FEP patients (95 females and 114 males) were reassessed after a time window ranging from 8 to 16 years after their first contact with an EIS program (PAFIP) that we will call the 10-year PAFIP cohort. Multiple clinical, cognitive, functioning, premorbid, and sociodemographic variables were explored at 1-year, 3-year and 10-year follow-ups. At first contact, females were older at illness onset, had higher premorbid adjustment and IQ, and were more frequently employed, living independently, and accompanied by a partner and/or children. Existence of a schizophrenia diagnosis, and cannabis and alcohol consumption were more probable among men. During the first 3 years, women showed a significantly better response to minimal antipsychotic dosages and higher rates of recovery than men (50% vs. 30.8%). Ten years later, more females continued living independently and had partners, while schizophrenia diagnoses and cannabis consumption continued to be more frequent among men. Females also presented a lower severity of negative symptoms; however, functionality and recovery differences did not show significant differences (46.7% vs. 34.4%). Between the 3- and 10-year follow-up sessions, an increase in dosage of antipsychotics was observed. These results suggest that the better outcomes seen among women during the first 3 years (while they were treated in an EIS) were in the presence of more favourable premorbid and baseline characteristics. After an average period of 10 years, with the only difference being in negative symptoms course, outcomes for women approximated those of men, drawing particular attention to the increase in dosage of antipsychotic medication once FEP patients were discharged from the EIS program towards community-based services. These findings help to pose the question of whether it is advisable to target sexes and lengthen EIS interventions.

14 June 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SMSean R. McWhinney
Sean R. McWhinney
KBKatharina Brosch
Katharina Brosch
VCVince Calhoun
Vince Calhoun
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
NCNicolas A. Crossley
Nicolas A. Crossley
THTomas Hajek
Tomas Hajek
Schizophrenia is frequently associated with obesity, which is linked with neurostructural alterations. Yet, we do not understand how the brain correlates of obesity map onto the brain changes in schizophrenia. We obtained MRI-derived brain cortical and subcortical measures and body mass index (BMI) from 1260 individuals with schizophrenia and 1761 controls from 12 independent research sites within the ENIGMA-Schizophrenia Working Group. We jointly modeled the statistical effects of schizophrenia and BMI using mixed effects. BMI was additively associated with structure of many of the same brain regions as schizophrenia, but the cortical and subcortical alterations in schizophrenia were more widespread and pronounced. Both BMI and schizophrenia were primarily associated with changes in cortical thickness, with fewer correlates in surface area. While, BMI was negatively associated with cortical thickness, the significant associations between BMI and surface area or subcortical volumes were positive. Lastly, the brain correlates of obesity were replicated among large studies and closely resembled neurostructural changes in major depressive disorders. We confirmed widespread associations between BMI and brain structure in individuals with schizophrenia. People with both obesity and schizophrenia showed more pronounced brain alterations than people with only one of these conditions. Obesity appears to be a relevant factor which could account for heterogeneity of brain imaging findings and for differences in brain imaging outcomes among people with schizophrenia.

1 August 2019 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JTJakub Tomasik
Jakub Tomasik
SLSantiago G. Lago
Santiago G. Lago
JVJavier Vazquez-Bourgon
Javier Vazquez-Bourgon
SPSergi Papiol
Sergi Papiol
PSPaula Suárez-Pinilla
Paula Suárez-Pinilla
SBSabine Bahn
Sabine Bahn
Patients with schizophrenia show an increased risk of impaired glucose metabolism,1 yet the mechanism behind this association remains unknown. Multiple studies have attempted to identify the determinants of insulin resistance (IR) in schizophrenia, with evidence suggesting that it cannot be fully explained by disease duration, symptom severity, medication effects, obesity, or hormonal stress axis activation, and other interacting factors are likely involved.1 While family and genome-wide association studies have suggested a shared genetic vulnerability between schizophrenia and abnormal glucose metabolism,2 to our knowledge, a direct link between schizophrenia genetic risk and insulin resistance has not been investigated. Here, we examine the association between IR, schizophrenia polygenic risk, and treatment outcomes in first-episode, antipsychotic-naive patients with schizophrenia and matched healthy individuals while controlling for demographic, lifestyle, and clinical factors.